Schonfeld Strategic Advisors’s Novo Nordisk NVO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.75M	Buy	+102,040	New	+$4.83M	0.03%	584
2025 Q4	–	Sell	-557,519	Closed	-$28.5M	–	2422
2025 Q3	$30.9M	Buy	+557,519	New	+$32.6M	0.18%	98
2025 Q2	–	Sell	-156,635	Closed	-$10.9M	–	2389
2025 Q1	$10.9M	Buy	+156,635	New	+$12.9M	0.07%	292
2024 Q4	–	Sell	-70,925	Closed	-$8.45M	–	2275
2024 Q3	$8.45M	Buy	+70,925	New	+$9.46M	0.06%	348
2024 Q2	–	Sell	-3,200	Closed	-$411K	–	2448
2024 Q1	$411K	Buy	+3,200	New	+$381K	﹤0.01%	1543
2023 Q3	–	Sell	-200	Closed	-$16.2K	–	2129
2023 Q2	$16.2K	Sell	200 -2,000	-91%	-$163K	﹤0.01%	1901
2023 Q1	$175K	Buy	+2,200	New	+$156K	﹤0.01%	1574
2022 Q4	–	Sell	-7,600	Closed	-$379K	–	2879
2022 Q3	$379K	Sell	7,600 -101,060	-93%	-$5.41M	﹤0.01%	1940
2022 Q2	$6.05M	Sell	108,660 -110,502	-50%	-$6.13M	0.06%	417
2022 Q1	$12.2M	Buy	+219,162	New	+$11.2M	0.11%	227
2021 Q4	–	Sell	-103,884	Closed	-$4.99M	–	2411
2021 Q3	$4.99M	Buy	103,884 +50,484	+95%	+$2.44M	0.05%	439
2021 Q2	$2.24M	Sell	53,400 -64,948	-55%	-$2.52M	0.02%	672
2021 Q1	$3.99M	Sell	118,348 -1,052	-0.9%	-$37.5K	0.05%	491
2020 Q4	$4.17M	Buy	+119,400	New	+$4.13M	0.06%	437
2020 Q1	–	Sell	-10,366	Closed	-$300K	–	1399
2019 Q4	$300K	Buy	+10,366	New	+$287K	0.01%	968
2018 Q4	–	Sell	-62,520	Closed	-$1.47M	–	1191
2018 Q3	$1.47M	Buy	62,520 +396	+0.6%	+$9.66K	0.07%	352
2018 Q2	$1.43M	Buy	+62,124	New	+$1.48M	0.08%	332
2017 Q4	–	Sell	-53,086	Closed	-$1.28M	–	837
2017 Q3	$1.28M	Buy	+53,086	New	+$1.2M	0.12%	226
2017 Q1	–	Sell	-39,756	Closed	-$713K	–	694
2016 Q4	$713K	Sell	39,756 -76,566	-66%	-$1.39M	0.09%	275
2016 Q3	$2.42M	Buy	+116,322	New	+$2.88M	0.41%	61
2016 Q2	–	Sell	-12,760	Closed	-$346K	–	499
2016 Q1	$346K	Buy	+12,760	New	+$342K	0.14%	197

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Schonfeld Strategic Advisors's NVO Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Novo Nordisk (NVO) in Q1 2026: 102,040 shares worth $3.75M. The stake represents 0.03% of the portfolio and ranks #584 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in NVO as recently as Q3 2025.

Schonfeld Strategic Advisors first reported a position in NVO in Q1 2016 and has held it in 21 quarters since. The position peaked at $30.9M in Q3 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Schonfeld Strategic Advisors held 102,040 shares of Novo Nordisk worth $3.75M as of Q1 2026.
Novo Nordisk was a new Schonfeld Strategic Advisors position in Q1 2026.
Novo Nordisk made up 0.03% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #584 holding.
Schonfeld Strategic Advisors first reported a position in Novo Nordisk in Q1 2016 and has held it in 21 quarters since.
Schonfeld Strategic Advisors's Novo Nordisk position peaked at $30.9M in Q3 2025.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.